Literature DB >> 21984372

CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion.

Niko Bretz1, Aurelia Noske, Sascha Keller, Natalie Erbe-Hofmann, Thomas Schlange, Alexei V Salnikov, Gerd Moldenhauer, Glen Kristiansen, Peter Altevogt.   

Abstract

CD24 is a glycosyl-phosphatidylinositol-anchored protein with mucin-type structure that resides exclusively in membrane microdomains. CD24 is often highly expressed in carcinomas and correlates with poor prognosis. Experimentally, the over-expression or depletion of CD24 alters cell proliferation, adhesion, and invasion in vitro and tumor growth in vivo. However, little is known about the mechanisms by which CD24 mediates these cellular effects. Here we have studied the mechanism of CD24-dependent cell invasion using transient CD24 knock-down or over-expression in human cancer cell lines. We show that CD24 depletion reduced tumor cell invasion and up-regulated expression of Tissue Factor Pathway Inhibitor 2 (TFPI-2), a potent inhibitor of extracellular matrix degradation that can block metastases formation and tumor cell invasion. Over-expression of CD24 in A125 cells resulted in reduced TFPI-2 expression and enhanced invasion. We provide evidence that the activity of c-Src is reduced upon CD24 knock-down. The silencing of c-Src, similar to CD24, was able to enhance TFPI-2 expression and reduce tumor cell invasion. An inverse expression of CD24 and TFPI-2 was observed by immunohistochemical analysis of primary breast cancers (N = 1,174). TFPI-2 expression was highest in CD24 negative samples and lowered with increasing CD24 expression. Patients with a CD24 low/TFPI-2 high phenotype showed significantly better survival compared to CD24 high/TFPI-2 low patients. Our results provide evidence that CD24 can regulate cell invasion via TFPI-2 and suggests a role of c-Src in this process.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984372     DOI: 10.1007/s10585-011-9426-4

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  58 in total

1.  Arl2 and Arl3 regulate different microtubule-dependent processes.

Authors:  Chengjing Zhou; Leslie Cunningham; Adam I Marcus; Yawei Li; Richard A Kahn
Journal:  Mol Biol Cell       Date:  2006-03-08       Impact factor: 4.138

2.  Intracellular CD24 inhibits cell invasion by posttranscriptional regulation of BART through interaction with G3BP.

Authors:  Keisuke Taniuchi; Isao Nishimori; Michael A Hollingsworth
Journal:  Cancer Res       Date:  2011-01-25       Impact factor: 12.701

3.  The genes for a mouse hematopoietic differentiation marker called the heat-stable antigen.

Authors:  R H Wenger; M Ayane; R Bose; G Köhler; P J Nielsen
Journal:  Eur J Immunol       Date:  1991-04       Impact factor: 5.532

4.  Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line.

Authors:  J A Zarn; S M Zimmermann; M K Pass; R Waibel; R A Stahel
Journal:  Biochem Biophys Res Commun       Date:  1996-08-14       Impact factor: 3.575

5.  Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis.

Authors:  M P Herman; G K Sukhova; W Kisiel; D Foster; M R Kehry; P Libby; U Schönbeck
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

6.  CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells.

Authors:  S Aigner; Z M Sthoeger; M Fogel; E Weber; J Zarn; M Ruppert; Y Zeller; D Vestweber; R Stahel; M Sammar; P Altevogt
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

7.  CD24 induces localization of beta1 integrin to lipid raft domains.

Authors:  Steffen Runz; Claudia T Mierke; Safwan Joumaa; Jürgen Behrens; Ben Fabry; Peter Altevogt
Journal:  Biochem Biophys Res Commun       Date:  2007-11-01       Impact factor: 3.575

8.  Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/gamma-secretase activity.

Authors:  Svenja Riedle; Helena Kiefel; Daniela Gast; Sandra Bondong; Silke Wolterink; Paul Gutwein; Peter Altevogt
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

9.  Heat-stable antigen (CD24) as ligand for mouse P-selectin.

Authors:  M Sammar; S Aigner; M Hubbe; V Schirrmacher; M Schachner; D Vestweber; P Altevogt
Journal:  Int Immunol       Date:  1994-07       Impact factor: 4.823

10.  Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells.

Authors:  X Cao; J Geradts; M W Dewhirst; H-W Lo
Journal:  Oncogene       Date:  2011-06-13       Impact factor: 9.867

View more
  27 in total

1.  Activation of tumour cell ECM degradation by thrombin-activated platelet membranes: potentially a P-selectin and GPIIb/IIIa-dependent process.

Authors:  J H Pang; L A Coupland; C Freeman; B H Chong; Christopher R Parish
Journal:  Clin Exp Metastasis       Date:  2015-05-16       Impact factor: 5.150

2.  Hypermethylation of TFPI2 correlates with cervical cancer incidence in the Uygur and Han populations of Xinjiang, China.

Authors:  Yuling Dong; Qiufen Tan; Lin Tao; Xiaolin Pan; Lijuan Pang; Weihua Liang; Wei Liu; Wenjie Zhang; Feng Li; Wei Jia
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

3.  CD24+ Ovarian Cancer Cells Are Enriched for Cancer-Initiating Cells and Dependent on JAK2 Signaling for Growth and Metastasis.

Authors:  Daniela Burgos-Ojeda; Rong Wu; Karen McLean; Yu-Chih Chen; Moshe Talpaz; Euisik Yoon; Kathleen R Cho; Ronald J Buckanovich
Journal:  Mol Cancer Ther       Date:  2015-05-12       Impact factor: 6.261

4.  CD24 controls Src/STAT3 activity in human tumors.

Authors:  Niko P Bretz; Alexei V Salnikov; Claudia Perne; Sascha Keller; Xiaoli Wang; Claudia T Mierke; Mina Fogel; Natalie Erbe-Hofmann; Thomas Schlange; Gerhard Moldenhauer; Peter Altevogt
Journal:  Cell Mol Life Sci       Date:  2012-07-04       Impact factor: 9.261

5.  Plasma D-dimer value as a predictor of malignant lymph node involvement in operable non-small cell lung cancer.

Authors:  Feng Chen; Min-Jie Wang; Jia Li; Cui-E Yan; Xiao-Hong Han; Zong-Yong Wu; Jun Qi
Journal:  Tumour Biol       Date:  2015-06-19

6.  A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.

Authors:  Ilana Chefetz; Edward Grimley; Kun Yang; Linda Hong; Ekaterina V Vinogradova; Radu Suciu; Ilya Kovalenko; David Karnak; Cynthia A Morgan; Mikhail Chtcherbinine; Cameron Buchman; Brandt Huddle; Scott Barraza; Meredith Morgan; Kara A Bernstein; Euisik Yoon; David B Lombard; Andrea Bild; Geeta Mehta; Iris Romero; Chun-Yi Chiang; Charles Landen; Benjamin Cravatt; Thomas D Hurley; Scott D Larsen; Ronald J Buckanovich
Journal:  Cell Rep       Date:  2019-03-12       Impact factor: 9.423

7.  Elevated hippocampal CD24 in astrocytes participates in neural regeneration possibly via activating SHP2/ERK pathway after experimental traumatic brain injury in mice.

Authors:  Xuan Gao; Han Wang; Yong-Yue Gao; Xiao-Ming Zhou; Tao Tao; Guang-Jie Liu; Yan Zhou; Wei Li; Chun-Hua Hang
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

8.  Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis.

Authors:  Jason E Duex; Charles Owens; Ana Chauca-Diaz; Garrett M Dancik; Lauren A Vanderlinden; Debashis Ghosh; Mariah Z Leivo; Donna E Hansel; Dan Theodorescu
Journal:  Cancer Res       Date:  2017-07-03       Impact factor: 12.701

9.  CD44+/CD24- breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties.

Authors:  Hongmei Sun; Jun Jia; Xiaoli Wang; Bo Ma; Lijun Di; Guohong Song; Jun Ren
Journal:  Clin Transl Oncol       Date:  2012-07-20       Impact factor: 3.405

10.  Structure-Based Optimization of a Novel Class of Aldehyde Dehydrogenase 1A (ALDH1A) Subfamily-Selective Inhibitors as Potential Adjuncts to Ovarian Cancer Chemotherapy.

Authors:  Brandt C Huddle; Edward Grimley; Cameron D Buchman; Mikhail Chtcherbinine; Bikash Debnath; Pooja Mehta; Kun Yang; Cynthia A Morgan; Siwei Li; Jeremy Felton; Duxin Sun; Geeta Mehta; Nouri Neamati; Ronald J Buckanovich; Thomas D Hurley; Scott D Larsen
Journal:  J Med Chem       Date:  2018-09-28       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.